Overview

Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants

Status:
Completed
Trial end date:
2021-10-11
Target enrollment:
Participant gender:
Summary
Primary Objective: To assess the pharmacokinetic parameters of SAR443820 after ascending single oral doses in healthy East Asian (Chinese and Japanese) adult participants. Secondary Objective: To assess the tolerability and safety of SAR443820 after ascending single oral doses in healthy East Asian (Chinese and Japanese) adult participants
Phase:
Phase 1
Details
Lead Sponsor:
Sanofi